Drug Or Compound Screening Involving Gene Expression Patents (Class 435/6.13)
-
Patent number: 8883144Abstract: The present invention relates to agonists of Neprilysin and their use in preventing and treating pulmonary vascular remodeling. Also described are diagnostic and screening applications stemming from the inventor's discovery that Neprilysin is expressed at reduced levels in disease tissues.Type: GrantFiled: September 1, 2011Date of Patent: November 11, 2014Assignee: The Regents of the University of Colorado, a body corporateInventor: Edward C. Dempsey
-
Publication number: 20140329787Abstract: The present invention relates to a novel Phytophthora phospholipase C and uses thereof, methods of identifying modulators and inhibitors of a biological function of the phospholipase C, and methods of inhibiting Phytophthora growth comprising inhibiting a biological function of a novel Phytophthora phospholipase C.Type: ApplicationFiled: October 17, 2012Publication date: November 6, 2014Inventors: Dean Ian Phillips, Peter Luke Beech
-
Publication number: 20140329809Abstract: A process for the characterization of rosacea is disclosed. The process can include identifying for the first time new markers in leukocyte recruitment as well as the therapeutic applications targeting rosacea.Type: ApplicationFiled: October 26, 2012Publication date: November 6, 2014Applicant: GALDERMA RESEARCH & DEVELOPMENTInventors: Isabelle Carlavan, Martin Steinhoff
-
Publication number: 20140331341Abstract: The present invention relates to methods and compositions for high content drug screening in C. elegans which may be used to identify compounds that treat disorders associated with protein aggregation.Type: ApplicationFiled: July 18, 2014Publication date: November 6, 2014Applicant: University of Pittsburgh - of the Commonwealth System of Higher EdUcationInventors: Stephen C. Pak, David H. Perlmutter, Gary A. Silverman
-
Publication number: 20140323551Abstract: The present invention describes methods of treating cancer, cancer metastasis, and drug resistant cancers using miRNA inhibitors; for example, inhibitors of miR-409-5p. Also described are methods of using the miRNA as biomarkers; for example, to predict responsiveness to a cancer drug, to detect a disease state of cancer.Type: ApplicationFiled: November 30, 2012Publication date: October 30, 2014Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Leland W.K. Chung, Sajni Josson, Murali Gururajan, Anjali Jain
-
Publication number: 20140323346Abstract: The present disclosure generally relates to protein binding agents, such as protein kinase binding agents of general Formula (I). The protein binding agents may be provided attached to a solid support and may be used, for example, to detect the presence of a broad range of proteins in a sample. Methods of synthesizing the protein binding agents, and kits comprising the protein binding agents, are also disclosed.Type: ApplicationFiled: November 21, 2012Publication date: October 30, 2014Applicant: Garvan Institute of Medical ResearchInventors: Roger John Daly, Ian Peter Holmes, Ian Street, Scott Raymond Walker
-
Publication number: 20140323348Abstract: Disclosed are methods of promoting and/or enhancing G-Protein Coupled Receptor (GPCR) localization to the cell membrane and/or cell surface; methods of promoting and/or enhancing GPCR functional expression; and methods and assays for screening or identifying ligands (e.g., agonists or antagonists) that bind GPCRs. Also provided are vectors, recombinant cells, and stable cell lines for use in the methods and assays.Type: ApplicationFiled: November 30, 2012Publication date: October 30, 2014Inventors: Hiroaki Matsunami, Yue Jiang, Ming-Shan Chien
-
Publication number: 20140325691Abstract: The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.Type: ApplicationFiled: June 5, 2014Publication date: October 30, 2014Applicant: Sangamo BioSciences, Inc.Inventors: George Norbert Cox III, Casey C. Case, Stephen P. Eisenberg, Eric Edward Jarvis, Sharon Kaye Spratt
-
Patent number: 8871445Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.Type: GrantFiled: April 23, 2014Date of Patent: October 28, 2014Assignees: The Broad Institute Inc., Massachusetts Institute of Technology, President and Fellows of Harvard CollegeInventors: Le Cong, Feng Zhang
-
Publication number: 20140315754Abstract: Embodiments are directed to methods and compositions for determining the level of DCLK1-S in a sample and treating a subject having elevated levels of DCLK1-S.Type: ApplicationFiled: April 5, 2014Publication date: October 23, 2014Applicant: The Board of Regents of the University of Texas SystemInventors: Pomila Singh, Shubhashish Sarkar, Malaney O'Connell
-
Publication number: 20140314723Abstract: The disclosure relates to cell culture vessels comprising fabricated cell culture surfaces providing means for efficient corneal endothelial cell growth and the use of the cultured cells in the repair of corneal tissue damage.Type: ApplicationFiled: April 17, 2014Publication date: October 23, 2014Applicant: National University of SingaporeInventors: King Fai Evelyn Yim, Kim Kiat Teo, Stephanie Koo
-
Publication number: 20140314765Abstract: The present invention provides a set of DETERMINANTS (e.g., genes and gene products) that can accurately inform about the risk of cancer progression and recurrence, as well as methods of their use.Type: ApplicationFiled: June 26, 2012Publication date: October 23, 2014Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Ronald A. DePinho, Zhihu Ding, Chang-Jiun Wu, Lynda Chin
-
Patent number: 8865406Abstract: The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are compositions and methods related to components of a CRISPR complex particularly comprising a Cas ortholog enzyme.Type: GrantFiled: March 24, 2014Date of Patent: October 21, 2014Assignees: The Broad Institute Inc., Massachusetts Institute of TechnologyInventors: Feng Zhang, Fei Ran
-
Publication number: 20140308675Abstract: Provided is a test method that allows mutagenicity on a mammal including a human to be confirmed accurately and simply in a short time. Specifically, provided is a mutagenicity test method, including the steps of: (1) culturing a transformant of a mammalian cell harboring a recombinant vector including a p53 binding sequence, a minimal promoter that can function in the mammalian cell, and a reporter gene linked so that the gene can be expressed by the minimal promoter, in the presence of a test substance for a predetermined time; and (2) assessing whether or not the test substance affects an expression amount of the reporter gene in the transformant by comparing an expression amount of the reporter gene in the transformant cultured in the step (1) to an expression amount of the reporter gene in the transformant free of contact with the test substance.Type: ApplicationFiled: October 11, 2012Publication date: October 16, 2014Inventors: Taisei Mizota, Katsutoshi Ohno, Toshihiro Yamada
-
Patent number: 8859207Abstract: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.Type: GrantFiled: September 14, 2010Date of Patent: October 14, 2014Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Texas at El PasoInventors: Leonard M. Neckers, Marc B. Cox, Jane B. Neckers, Yeong Sang Kim, Aki Iwai, Yangmin Ning, Johanny Tonos de Leon, Heather Balsiger
-
Publication number: 20140302512Abstract: The present invention relates to methods for detecting for the presence of an agent that putatively causes or potentiates DNA damage comprising subjecting a cell (containing a DNA sequence encoding Gaussia luciferase (GLuc) reporter protein operatively linked to a human GADD45? gene promoter and a human GADD45? gene regulatory element arranged to activate expression of the DNA sequence in response to DNA damage) to an agent; and monitoring the expression of the GLuc reporter protein from the cell. The invention also concerns expression cassettes, vectors and cells which may be used according to such a method and also modified media that may be employed in assays and in preferred embodiments of the method of the invention.Type: ApplicationFiled: October 14, 2013Publication date: October 9, 2014Applicant: GENTRONIX LIMITEDInventors: Adam Rabinowitz, Richard Walmsley, Matthew Tate
-
Publication number: 20140302181Abstract: The present invention discloses a drug screening method, drugs promoting extracellular matrix protein crosslinking and their applications, the said drug screening method, is used to screen out materials promoting the expression of LOXL1 gene, wherein, the said drug screening method contains the following steps: A, Construct the 2nd generation lentiviral vector used to control the ZsGreen expression by human LOXL 1 gene promoter. B, Infect human fibroblasts with the 2nd generation lentiviral vector, and construct the new human fibroblasts which integrate PLOXL1-ZsGreen components. C, Drug screening: Inoculate the said human fibroblasts integrating PLOXL1-ZsGreen components into culture medium. Add the analyte into the cell culture medium containing human fibroblast cells. After culturing, detect the green fluorescence intensity of these fibroblast cells, then decide if the analyte promotes LOXL1 gene expression by checking if the green fluorescence intensity is increased.Type: ApplicationFiled: December 28, 2012Publication date: October 9, 2014Inventors: Xiaoqing Liu, Ming Ying, Lihua Jian
-
Publication number: 20140302513Abstract: A method for qualitatively assessing products used in in vitro fertilization is provided. Also disclosed is an improved quality control assay for use in clinical Assisted Reproductive Technologies (ART).Type: ApplicationFiled: April 9, 2014Publication date: October 9, 2014Inventors: Hsiao-Tzu Ni, Samira Es-Slami, Rebecca Susan Gilbert
-
Publication number: 20140302119Abstract: Microvesicles containing interfering RNAs, preparation methods and uses thereof are provided. Pharmaceutical compositions and kits comprising the microvesicles containing interfering RNAs are also provided. Microvesicles containing interfering RNAs, pharmaceutical compositions and kits comprising such microvesicles can be used to study the effects of interfering RNAs on receptor cells. As microvesicles containing interfering RNAs can stably, high efficiently and specifically deliver interfering RNAs, microvesicles containing interfering RNAs can be used to treat related diseases.Type: ApplicationFiled: May 26, 2010Publication date: October 9, 2014Applicant: Micromedmark Biotech Co. Ltd.Inventors: Chenyu Zhang, Ke Zeng, Danqing Liu, Yujing Zhang, Hongwei Gu
-
Publication number: 20140302042Abstract: A set of biomarkers (e.g., genes and gene products) that can accurately inform about the risk of cancer progression and recurrence, as well as methods of their use are disclosed.Type: ApplicationFiled: June 29, 2012Publication date: October 9, 2014Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Lynda Chin, Kenneth L. Scott, Papia Ghosh, Kunal Rai, Chengyin Min
-
Publication number: 20140303020Abstract: [Problem] To provide a method for assessing myelodysplastic syndrome or myeloid tumor predisposition, on the basis of a genetic diagnosis using massively parallel sequencing technology, as well as a peptide and antibody therefor, and a method for screening for candidate therapeutic drugs or prophylactic drugs for myelodysplastic syndrome or myeloid tumor. [Solution] A method for assessing whether or not there is a predisposition for the occurrence of myelodysplastic syndrome or myeloid tumor, wherein the method comprises a step for using a sample that includes a subject's human genes and detecting a mutation in at least one gene from among the U2AF35 gene, the ZRSR2 gene, the SFRS2 gene, or the SF3B1 gene.Type: ApplicationFiled: August 2, 2012Publication date: October 9, 2014Applicant: The University of TokyoInventors: Seishi Ogawa, Masashi Sanada, Kenichi Yoshida
-
Publication number: 20140303035Abstract: The present invention provides nucleic acid constructs that encode fusion peptides comprising a bioluminescent protein and a precursor of a secreted peptide or protein expressed at the cell surface and high throughput screening assays using same.Type: ApplicationFiled: November 7, 2012Publication date: October 9, 2014Inventors: Sean Burns, David Altshuler, Amedeo Vetere
-
Publication number: 20140303078Abstract: Work described herein provides, in one embodiment, a method for increasing proliferation or replication of pancreatic beta cells in a subject in need thereof, comprising administering to said subject an effective amount of an agent that increases the level or activity of hepatocellular carcinoma-associated protein TD26 (TD26), thereby increasing proliferation or replication of pancreatic beta cells. Such an agent may function by, for example, increasing the level of active TD26 in the subject or by increasing the functional activity of TD26 in the subject.Type: ApplicationFiled: June 10, 2012Publication date: October 9, 2014Applicant: President and Fellows of Harvard CollegeInventors: Douglas A. Melton, Peng Yi
-
Publication number: 20140303231Abstract: The invention features therapeutic compositions comprising agents useful for the treatment or prevention of pruritis, and methods useful for identifying such agents.Type: ApplicationFiled: January 24, 2014Publication date: October 9, 2014Applicant: The Johns Hopkins UniversityInventors: Xinzhong Dong, Qin Liu, David J. Anderson
-
Publication number: 20140303090Abstract: A Smac mimetic therapy wherein the Smac mimetic is selected and developed based at least in part on its poor inhibition of XIAP-dependent processes.Type: ApplicationFiled: April 7, 2014Publication date: October 9, 2014Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventors: Stephen M. Condon, Srinivas K. Chunduru, Yasuhiro Mitsuuchi, James Vince, John Silke
-
Publication number: 20140303029Abstract: Methods and genetic sequences are described for use in determining the diagnosis, subtype, prognosis, and disease course of high-grade gliomas, such as glioblastoma multiforme. One such method includes determining increased expression of at least one gene on a chromosome segment in cells of the glioma, the segment being 17:57,851,812-17:57,973,757; 7:127,892,509-7:127,947,649; 12:33,854-12:264,310; or 19:33,329,393-19:35,322,055; and estimating, based on the expression, a predicted length of survival, a probability of survival, or a predicted response to a therapy for the glioma.Type: ApplicationFiled: October 31, 2012Publication date: October 9, 2014Inventor: Orly Alter
-
Patent number: 8853279Abstract: The invention relates to a method for determining whether a patient suffering from a condition that is susceptible to treatment with a compound that activates the brain serotonin system is susceptible or resistant to treatment with the compound. The method includes establishing whether the patient is a pre-adult, a transition age patient, or an adult and observing whether the genome of the patient contains at least one copy of a BDNF allele having a genetic alteration. The method further includes correlating the presence of the allele containing the genetic alteration with susceptibility or resistance of the patient to the treatment with the compound, wherein a pre-adult patient containing the genetic alteration is correlated as being susceptible to the treatment; a transition age patient containing the genetic alteration is correlated as being susceptible or resistant to the treatment; and an adult patient containing the genetic alteration is correlated as being resistant to the treatment.Type: GrantFiled: June 16, 2009Date of Patent: October 7, 2014Assignee: Cornell UniversityInventors: Francis S. Lee, Barbara Hempstead, James Kocsis, Kevin Bath
-
Patent number: 8852880Abstract: Method of in vitro measurement of the presence of factors that are able to neutralize asparaginase activity in a sample of blood, plasma, serum or derived medium that may contain asparaginase neutralizing factors, obtained from a patient, comprising mixing of said sample with asparaginase, incubation of said mixture, then measurement of the residual asparaginase activity in the mixture and determination or quantification of the presence of said neutralizing factors. Method for predicting the efficacy of a treatment with asparaginase.Type: GrantFiled: November 6, 2009Date of Patent: October 7, 2014Assignee: Erytech PharmaInventor: Yann Godfrin
-
Publication number: 20140295449Abstract: The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-Dilinoley 1-4-dimethylaminomethyl-[1,3]-dioxolane by screening for an effect of the agent on the liver of a model subject.Type: ApplicationFiled: October 21, 2013Publication date: October 2, 2014Applicant: Tekmira Pharmaceuticals, Inc.Inventors: Marco A. Ciufolini, Thomas D. Madden, Michael J. Home, Barbara Mui, Antonin de Fougerolles, Tatiana Novobrantseva, Anna Borodovsky, Akin Akinc, Mark Tracy, Pieter Rutter Cullis
-
Publication number: 20140296218Abstract: The present invention relates in some aspects to super-enhancers and related compositions, methods, and agents that are useful for modulating expression of cell type-specific genes that are required for maintenance of cell identity (e.g., embryonic stem cell identity) or maintenance of a disease state (e.g., cancer).Type: ApplicationFiled: October 25, 2013Publication date: October 2, 2014Applicant: Whitehead Institute for Biomedical ResearchInventors: Richard A. Young, Warren Whyte, Denes Hnisz, Jakob Loven, Heather Hoke, David Orlando, Charles Y. Lin, Tony Lee
-
Publication number: 20140294729Abstract: The invention relates to methods for identifying compounds and compositions that target cancer stem cells. In some aspects, the invention relates to treatment methods that use compounds and compositions that specifically target cancer stem cells for inhibiting the growth and/or survival of cancer stem cells in a subject in need thereof. Other aspects of the invention relate to the use of cancer stem cell biomarkers in the selection of a treatment for inhibiting the growth and/or survival of cancer stem cells in a subject in need thereof.Type: ApplicationFiled: October 28, 2013Publication date: October 2, 2014Applicants: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, President and Fellows of Harvard CollegeInventors: PIYUSH GUPTA, TAMER T. ONDER, ERIC S. LANDER, ROBERT A. WEINBERG, SENDURAI MANI, MAI-JING LIOA
-
Publication number: 20140296091Abstract: There is provided a diagnostic reagent for use in the detection of M. bovis or M. tuberculosis infection in an animal, comprising a peptide which has an epitope from Mycobacterium bovis hypothetic protein Mb3645c (SEQ ID NO: 1) or an epitope from a polypeptide having at least 76% identity with SEQ ID NO: 1.Type: ApplicationFiled: February 21, 2014Publication date: October 2, 2014Inventors: Hans Martin Vordermeier, Benjamin Sidders, Neil Graham Stoker, Katie Ewer
-
Publication number: 20140296097Abstract: There are provided a composition for determining the efficacy of a c-Met antibody including marker genes and a method for determining the efficacy of a c-Met antibody using the marker genes.Type: ApplicationFiled: March 28, 2014Publication date: October 2, 2014Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: BO GYOU KIM, KYUNG AH KIM
-
Publication number: 20140294726Abstract: Methods for diagnosing and treating Alzheimer's disease are provided. In particular, methods of restoring blood-brain barrier integrity and/or promoting vascular reversion in a person suffering from Alzheimer's disease by administering an anti-angiogenic agent or an agent that is capable of restoring tight junction integrity. Methods of preventing or delaying the onset of Alzheimer's disease in a subject are also provided.Type: ApplicationFiled: July 18, 2012Publication date: October 2, 2014Inventors: Wilfred Jefferies, Kaan E. Biron, Dara L. Dickstein
-
Publication number: 20140296223Abstract: This invention relates to a method for regulating skin pigmentation of a subject, comprising the step of administering the agent for inhibiting the expression or activation of Microphthalmia Transcription Factor (MITF) to the subject who is in need of regulation of skin pigmentation.Type: ApplicationFiled: August 31, 2012Publication date: October 2, 2014Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: David E. Fisher, Rizwan Haq, Hans Ragnar Valdemar Widlund
-
Patent number: 8846030Abstract: Agents and methods to alter rAAV transduction are provided.Type: GrantFiled: December 13, 2005Date of Patent: September 30, 2014Assignee: University of Iowa Research FoundationInventors: John F. Engelhardt, Dongsheng Duan
-
Patent number: 8846311Abstract: Methods for identifying a therapeutic agent for treating a Germinal Center Kinase (GCK)-Like Kinase (GLK)-mediated disease are disclosed. Methods for detecting a modulation of GLK signaling by a test compound are disclosed. Also disclosed are methods for detecting the presence and/or severity of an autoimmune disease and/or cancer.Type: GrantFiled: July 13, 2012Date of Patent: September 30, 2014Assignee: National Health Research InstitutesInventors: Tse-Hua Tan, Huai-Chia Chuang
-
Patent number: 8846932Abstract: Disclosed are methods and compositions for modulating the function of transcription factors, especially transcription factors that recruit epigenetic regulators (histone modifying enzymes) to specific DNA promoters. The targeted transcription factors include but are not limited to the myocyte enhancing factor (MEF2), the forkhead/winged helix transcription factor FOXP3 and the transcription factor GATA3. Also disclosed are small molecule modulators of MEF2 and its associated factors that include but not limited to histone deacetylases (HDACs), p300/CBP and Cabin1 and the therapeutic applications thereof.Type: GrantFiled: March 13, 2013Date of Patent: September 30, 2014Assignee: University of Southern CaliforniaInventors: Lin Chen, Nimanthi Jayathilaka, Aidong Han, Nicos A. Petasis
-
Patent number: 8846308Abstract: Methods of identifying immune response modulators are disclosed. Some methods comprise identifying chemical candidates that modulate oligomerization of FOXP3 and/or fragments thereof comprising the Zinc-LeuZip domains. Some methods comprise identifying chemical candidates that modulate the hetero-oligomerization of FOXP1 with FOXP3 and/or fragments thereof comprising the Zinc-LeuZip domains. Some methods comprise identifying chemical candidates that modulate interaction of IL-2 promoter with FOXP3 and/or fragments thereof comprising the Zinc-LeuZip domains. Method of treating individuals who have or are suspected of having autoimmune disease, inflammatory disease, cell, tissue or organ transplantation, or coronary artery disease, and methods of treating individuals who have or are suspected of having infectious disease, cancer, or who are immunocompromised or undergoing vaccination are disclosed.Type: GrantFiled: June 6, 2008Date of Patent: September 30, 2014Assignee: The Trustees of the University of PennsylvaniaInventors: Mark I. Greene, Bin Li
-
Publication number: 20140288162Abstract: Methods and compositions are provided for treating human synovial sarcoma (SS). Also provided are screens to identify therapeutics for the treatment of synovial sarcoma. These methods, compositions, and screens are based on the discovery that promoting the assembly of wild type BAF (also called mSWI/SNF) complexes in SS cells by increasing levels of wild type SS18 and/or decreasing levels of SS18-SSX fusion protein leads to the cessation of proliferation of malignant cells in synovial sarcoma.Type: ApplicationFiled: March 13, 2014Publication date: September 25, 2014Inventors: Cigall Kadoch, Gerald R. Crabtree
-
Publication number: 20140288093Abstract: The present disclosure provides technologies relating to lysosomal activation. The disclosure provides several strategies for increasing level and/or activity of lysosomal enzyme, and furthermore demonstrates the surprising applicability of such strategies in the treatment and/or prophylaxis of certain proteinopathies. Among other things, the present invention provides methods and compositions for the treatment and/or prophylaxis of proteinopathies other than lysosomal storage diseases through lysosomal activation. In particular, the present disclosure provides methods and compositions for the treatment and/or prophylaxis of neurodegenerative proteinopathies, and in particular those associated with accumulation of ?-synuclein. The present disclosure specifically provides methods and compositions for the treatment and/or prophylaxis of Parkinson's disease.Type: ApplicationFiled: June 22, 2012Publication date: September 25, 2014Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Dmitri Krainc, Joseph R. Mazzulli
-
Publication number: 20140286952Abstract: The chain of events that explains calcitonin receptor (CTR)-stimulated invasion and metastasis of prostate cancer cells was identified. The CTR-stimulated events depend on the interaction of CTR with the PDZ3 domain of ZO-1. Small peptides and small molecules were identified that inhibit this interaction. The small inhibitory peptides were synthesized and can be used to attenuate or inhibit metastasis in solid cancer tumors.Type: ApplicationFiled: March 30, 2012Publication date: September 25, 2014Applicant: Board of Supervisors for the University of Louisia System, acting on behalf of the University of LouInventor: Girish V. Shah
-
Publication number: 20140289882Abstract: The present inventions are directed to compositions and methods regarding the reprogramming of other cells (such as embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), MSCs, fibroblasts, hematopoietic stem cells, endothelian stem cells, adipocytes, chondrocytes, osteoblasts, osteoclasts and endothelial cells) into chondrogenic cells without introducing exogenous genes to the samples. In particular, the present inventions are directed to transducible materials that are capable of transducing into the biological samples but are not genes or causing genetic modifications. The present inventions also are directed to methods of reprogramming the path of biological samples or treating diseases using the tranducible compositions thereof.Type: ApplicationFiled: July 19, 2012Publication date: September 25, 2014Applicants: OREGON HEALTH AND SCIENCE UNIVERSITY, VIVOSCRIPT, INC.Inventors: Yong Zhu, Shili Wu, Jun Bao, Cong-Qiu Chu
-
Publication number: 20140287944Abstract: Markers for functionally mature ?-cells and methods of using these markers are disclosed.Type: ApplicationFiled: February 26, 2014Publication date: September 25, 2014Applicant: President and Fellows of Harvard CollegeInventors: Sinisa Hrvatin, Douglas A. Melton, Barak Blum
-
Publication number: 20140274766Abstract: Methods for identifying subjects having, or at risk for developing, osteoarthritis or other cartilage degenerative conditions by measuring levels of expression of F-spondin are provided. Assays, kits and methods for determining and assaying the presence of F-spondin in individual patients are disclosed. Oligonucleotide probes and primers for use in the assays, kits and methods are described. Assays and methods are disclosed for identifying candidate compounds that modulate F-spondin levels of expression and/or function or for determining and evaluating an individual's response to drugs and therapeutic agents, are provided. The invention further relates to the modulation of F-spondin, particularly the inhibition of F-spondin, for increasing or stimulating bone formation and/or growth and mediating the alleviation of bone disease, disorders or conditions.Type: ApplicationFiled: January 15, 2014Publication date: September 18, 2014Inventors: Steven B. Abramson, Mukundan Attur, Glyn Palmer, Ashok Amin
-
Publication number: 20140274739Abstract: Flow chambers are provided. In some embodiments, the flow chambers include an inner panel having at least one flow channel having an inlet/outlet opening on each end thereof formed therein, wherein the inlet/outlet openings are adapted to releasably receive a septum; one or more ports adapted to releasably receive a plug and for at least liquid communication with the at least one flow channel, and an outer frame that defines an outer portion of the at least one flow channel and that defines a perimeter of the flow chamber. In some embodiments, the flow chamber has overall dimensions of a standard multiwell plate and the at least one flow channel is located in a position that corresponds to a column location of the standard multiwell plate. Also provided are methods for producing the presently disclosed flow chambers and employing the same to assay biological features of cultured cells and/or tissues.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: UNIVERSITY OF CALGARYInventors: Kristina D. Rinker, Robert D. Shepherd
-
Publication number: 20140275073Abstract: The present disclosure provides methods of treating cancer and modifying a cancer treatment for a cancer with an anti-EGFR drug by creating PRDX6 expression profiles and using the profiles to evaluate and optionally modify treatment. The present disclosure also provides assays and systems for assessing sensitivity of a cancer to an anti-EGFR therapy.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Inventors: Edwin Chang, Lingyun Xu, Nick Hughes, Carsten H. Nielsen, Sanjiv S. Gambhir, Parag Mallick, Arutselvan Natarajan
-
Publication number: 20140271682Abstract: The invention generally relates to human biology discoveries and therapeutic and diagnostic compositions and methods based thereon. More particularly, the invention relates to human homeobox gene VentX and its control of macrophage terminal differentiation and activation, and related therapeutic and diagnostic compositions and methods of use, in particular in connection with inflammatory diseases.Type: ApplicationFiled: June 10, 2012Publication date: September 18, 2014Inventor: Zhenglun ZHU
-
Publication number: 20140256578Abstract: Methods and compositions for reducing expression of a mutant huntingtin (mHTT) protein in a cell are provided. Such methods include contacting the cell with an effective amount of a nucleic acid silencing agent targeting a differentiating polymorphism in RNA encoding the mHTT.Type: ApplicationFiled: February 6, 2014Publication date: September 11, 2014Applicant: The University of British ColumbiaInventors: Michael HAYDEN, Jeffrey CARROLL, Simon WARBY
-
Publication number: 20140255310Abstract: The present invention relates to methods of using a G protein-coupled receptor (GPCR) to identify whether a candidate compound is a modulator of atherogenesis. In certain embodiments, the GPCR couples to Gi. In certain embodiments, the GPCR is human. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of atherosclerosis and atherosclerotic disease, including coronary artery disease, myocardial infarction, peripheral arterial disease, and ischemic stroke. Agonists of the invention are additionally useful as therapeutic agents for the prevention or treatment of conditions related to MCP-1 expression, including but not limited to rheumatoid arthritis, Crohn's disease, and multiple sclerosis.Type: ApplicationFiled: February 13, 2014Publication date: September 11, 2014Applicant: ARENA PHARMACEUTICALS, INC.Inventors: Yaron Hakak, David J. Unett, Joel Gatlin, Chen W. Liaw